Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
A study titled “Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes,” published in the December 2023 issue of The American Journal of Managed Care® (AJMC®), was referenced in articles from Physician’s Weekly, DocWire News, and HCPLive. The study found that approximately 40% of patients with type 2 diabetes discontinued their second-line therapies within a year.
An article from Medriva referenced an article published on AJMC.com, the website of AJMC. The article, “Top 5 Conference Coverage of 2023,” collected the most-viewed items on AJMC.com that reported on new research presented at medical conferences that AJMC editors attended throughout the year, including the Annual Meeting of the American Society of Clinical Oncology and the European Hematology Association Congress.
Health Equity & Access Weekly Roundup: November 23, 2024
November 23rd 2024Americans are underinsured, even with employer-based health plans; a thorough critique of the lack of representation among Black patients in clinical trials showcases a persistent theme; systemic barriers in cardiology, breast cancer, and patent systems are examined.
Read More
FDA Accepts Resubmitted NDA for Ataluren in Nonsense Duchenne Muscular Dystrophy
November 22nd 2024The new drug application (NDA) includes data from a global placebo-controlled, 72-week study as well as findings from the STRIDE registry, an ongoing, observational, real-world study of ataluren in routine care.
Read More